PI3K Inhibitors Pipeline Insights, Clinical Trials, Emerging Therapies And Companies 2024

DelveInsight's,
“PI3K inhibitors Pipeline Insight 2024”
report provides comprehensive insights about 100+ companies and 100+ pipeline drugs based on PI3K inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the PI3K Inhibitors Pipeline. Dive into DelveInsight's comprehensive report today! @ PI3K Inhibitors Pipeline Outlook

Key Takeaways from the PI3K inhibitors Pipeline Report

• In September 2024:- Scorpion Therapeutics Inc.- Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 in participants with advanced solid tumors with P13Ka mutations.
• In September 2024:- Columbia University- Pilot Phase II Study of the PI3K Inhibitor Copanlisib in Combination With a Ketogenic Diet in the Treatment of Patients With Relapsed or Refractory Follicular Lymphoma or Endometrial Cancer. This is a multicenter, open label, pilot phase II study of the PI3K inhibitor copanlisib in combination with a ketogenic diet in the treatment of patients with one of the following malignancies: (a) relapsed or refractory (R/R) follicular lymphoma (FL), (b) R/R endometrial cancer (EC) with a documented activating mutation in PIK3CA or loss of phosphatase and tensin homolog (PTEN).
• DelveInsight's PI3K Inhibitors pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for PI3K Inhibitors treatment.
• The leading PI3K Inhibitors Companies such as TG Therapeutics, Pfizer, Incyte Corporation, Yuhan, Inflection Biosciences/AUM Biosciences, Onconova Therapeutics, UCB, and others.
• Promising PI3K Inhibitors Therapies such as Ribociclib, Fulvestrant, STX-478, Gedatolisib, Palbociclib, HMPL-689, and others.

Stay ahead with the most recent pipeline outlook for PI3K Inhibitors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ PI3K Inhibitors Treatment Drugs

PI3K Inhibitors Emerging Drugs Profile

• Umbralisib: TG Therapeutics

Umbralisib (TGR-1202) is an oral, once daily, dual inhibitor of PI3K delta and CK1 epsilon. Umbralisib has nanomolar potency to the delta isoform of PI3K and high selectivity over the alpha, beta, and gamma PI3K isoforms. Umbralisib also uniquely inhibits casein kinase 1 epsilon (CK1 epsilon), which may have both direct anti-cancer effects and may also modulate T-cell activity associated with immune-mediated adverse events seen with previous PI3K inhibitors. Currently, umbralisib is being evaluated in Phase IIb and Phase III trials in patients with NHL and CLL.

• Gedatolisib: Pfizer

Gedatolisib (PF-05212384) is an experimental drug for treatment of cancer in development by Pfizer. It works by targeting PI3K/mTOR. The Phase II clinical trials of gedatolisib for treatment of endometrial cancer and colorectal cancer were terminated early due to enrollment issues. It is currently in phase II stage of development.

• Parsaclisib: Incyte Corporation

Parsaclisib is a potent, highly selective, next-generation PI3Kδ inhibitor that is not associated with clinically meaningful transaminitis. It is in phase II stage of development.

• YH 25248: Yuhan

YH 25248 is an oral selective phosphatidylinositol 3-kinase (PI3K) delta inhibitor, being developed by Yuhan, for the treatment of cancer.

Explore groundbreaking therapies and clinical trials in the PI3K Inhibitors Pipeline. Access DelveInsight's detailed report now! @ New PI3K Inhibitors Drugs

PI3K inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

PI3K Inhibitors Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Unveil the future of PI3K Inhibitors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ PI3K Inhibitors Market Drivers and Barriers

Scope of the PI3K Inhibitors Pipeline Report

• Coverage- Global
• PI3K Inhibitors Companies- TG Therapeutics, Pfizer, Incyte Corporation, Yuhan, Inflection Biosciences/AUM Biosciences, Onconova Therapeutics, UCB, and others.
• PI3K Inhibitors Therapies- Ribociclib, Fulvestrant, STX-478, Gedatolisib, Palbociclib, HMPL-689, and others.
• PI3K Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• PI3K Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on PI3K Inhibitors Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ PI3K Inhibitors Companies, Key Products and Unmet Needs

Table of Content